Drug Type Small molecule drug |
Synonyms BAY1053048(ナトリウム塩), BAY85-3934(遊離塩基), Molidustat + [7] |
Target |
Mechanism HIF-PHs inhibitors(Hypoxia-inducible factor prolyl hydroxylase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (22 Jan 2021), |
Regulation- |
Molecular FormulaC13H14N8NaO2 |
InChIKeyHCTDSMITRFYAKD-UHFFFAOYSA-N |
CAS Registry1375799-59-9 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anemia in chronic kidney disease | JP | 22 Jan 2021 |
Phase 3 | 162 | jduusekftb(oedqsxqgnd) = ujlmsrthtn fwjixbasmh (ggjyoygfpv, 11.07 ~ 11.50) View more | Positive | 16 Sep 2021 | |||
ESA darbepoetin alfa | jduusekftb(oedqsxqgnd) = amcoerdsbb fwjixbasmh (ggjyoygfpv, 11.50 ~ 11.90) View more | ||||||
Phase 3 | 164 | ltmvzslosr(fattegfuhd) = otsucemrwn ukxyjvkvnb (obtdarfnjg, 11.48 ~ 11.85) View more | Non-inferior | 16 Sep 2021 | |||
darbepoetin alfa | ltmvzslosr(fattegfuhd) = rfjeisgtwh ukxyjvkvnb (obtdarfnjg, 11.31 ~ 11.74) View more | ||||||
Phase 3 | 51 | mdwwjnsvvg(domvwuvhrz) = uxqovpvjcd uwhrtrgffs (kfnqlgavpn, 40.3 - 68.9) | Positive | 26 Jul 2021 | |||
Phase 3 | - | 51 | hcvlwxnumy(ctjjxsdmpn) = afqlsqqzbd rsjxrakfte (xrfxneomks, 40.3 - 68.9) | Positive | 29 May 2021 | ||
Phase 3 | 25 | kkjpudkybd(vhagbmgggj) = ggkjqsbmpf sppoqamrav (ymbggrlted ) | Positive | 27 Jan 2021 | |||
Not Applicable | - | clhzptwryt(iiovpmjlfb) = Treatment emergent adverse events (TEAE) were reported in 69.6% of molidustat treated subjects and in 53.1% of subjects on darbepoetin jvhkyymhpl (ujwvqknhef ) View more | - | 14 May 2016 | |||
Phase 2 | 121 | dnpnsiawyk(bnzpmqjyam) = Treatment emergent adverse events (TEAE) were reported in 66.3% of all molidustat treated subjects and in 80% of subjects on placebo yitphsurxf (ogwnsmfpvm ) View more | Positive | 14 May 2016 | |||